Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia

Table 2 Pretreatment drug resistance mutations detected and their resistance pattern to common drugs

Sample ID	Age/Sex	Viral load (copies/ml)	Mutations type
Sample ID	Age/Sex	Viral load (copies/ml)	NNRTIs	Resistant to	NRTIs	Resistant to	PIs	Resistant to
MT416676	32/F	134,263	None		None		G73S*	ATV/ra
MT416698	37/F	124,246	K103N	EFV^c, NVP^c	None		None
MT416672	45/M	19,652	Y188L, H221Y, L234I*	ETR^a, DOR^c, EFV^c, NVP^c, RPV^c	Y115F, M184V	ABC^c, FTC^c, 3TC^c	None
MT416680	40/M	443,919	K101E	ETR^a, EFV^a,NVP^b, RPV^b, DORa	None		None
MT416667	25/F	66,791	V106A, E138A	ETR^a, DOR^c, EFV^b, NVPc, RPVa	None		None
MT416710	27/F	14,498	E138A	ETR^a, RPV^a	None		None

F Female, M Male, ATV/r Atazanavir/ritonavir, ABC Abacavir, FTC Emtricitabine, 3TC Lamivudine, DOR Doravirine, EFV Efavirenz, ETR Etravirine, NVP Nevirapine, RPV Rilpivirine, NRTI nucleoside reverse transcriptase inhibitor; NNRTI non-NRTI, PI protease inhibitor
^aLow-level resistance, ^bIntermediate-level drug resistance, ^cHigh-level drug resistance
Mutations in bold, are PDRMs by both IAS-USA and the CPR tool; Mutation in Italics are reported by IAS-USA only. While indicated by * only detected by the CPR tool

ISSN: 1742-4690